

# Winston-Salem, North Carolina 2026 MDF Regional Conference

**May 2nd**

A One-Day Event to Unite  
Community, Care, and a Cure for  
Myotonic Dystrophy



**Wake Forest University**  
School of Medicine

# Thank You to Our Conference Sponsors!



## Lead Sponsor



## Diamond Sponsor



## Platinum Sponsor



## Gold Sponsors



## Silver Sponsors



## Bronze Sponsors



## Supporting Sponsors



## Myotonic Dystrophy Foundation

663 13th Street, Suite 100, Oakland, California, 94612 | [www.myotonic.org](http://www.myotonic.org) | +1.415.800.7777 | [info@myotonic.org](mailto:info@myotonic.org)

2026 MDF Regional Conference - Wintston-Salem, NC



# Table of Contents



## 2026 MDF Regional Conference

May 2<sup>nd</sup> in Winston-Salem, North Carolina

Welcome Letter From the CEO .....	2
Agenda .....	3
<b>Sessions</b>	
General Sessions .....	4
Breakout Sessions .....	5 - 6
Myotonic Dystrophy at a Glance .....	7
<b>MDF Resources</b>	
For Individuals Affected by DM .....	8
For Healthcare Professionals .....	9
DM Drug Development Pipeline .....	10
International DM Awareness Day .....	11
Make the Most Out of Your Conference Experience .....	12
Continue Learning with MDF .....	13
Thank You to Our Amazing Volunteer Leaders .....	14
DM INSIGHT Survey Results .....	15
Join the Myotonic Dystrophy Family Registry (MDFR) .....	16



**Our Vision**  
We envision a world with treatments and a cure for myotonic dystrophy.

**Our Mission**  
The mission of the Myotonic Dystrophy Foundation is Community, Care, and a Cure.

- We support and connect the myotonic dystrophy community.
- We provide resources and advocate for care.
- We accelerate research toward treatments and a cure.

# Welcome Letter from the CEO



## Welcome to the 2026 MDF Regional Conference in Winston-Salem, NC!

On behalf of the Board of Directors and staff of the Myotonic Dystrophy Foundation (MDF), welcome to the 2026 MDF Regional Conference in Winston-Salem, North Carolina! We're honored to gather in our 18th year of conferences, bringing together over 100 community members from 14 states. Your presence strengthens and unites this community.



I extend my sincere appreciation to everyone who helped make this conference possible - especially our partners at Wake Forest University School of Medicine for hosting us today - and the many volunteers, advocates, and supporters who continue to move this mission forward.

MDF Regional Conferences are designed to bring our community closer together—creating space to share experiences, connect with clinicians and researchers, and learn about progress toward treatments and a cure. Since launching this regional format in 2024, we've seen the power of gathering locally: making it easier for families to participate, ask questions, and engage in meaningful conversations. This year's program reflects your input, with sessions tailored to meet the diverse needs of our community.



Today, there is real reason for hope. As we move closer than ever to the first approved treatments for myotonic dystrophy, your involvement is more important than ever. We encourage you to join the Myotonic Dystrophy Family Registry (MDFR) to help advance research and stay informed about new opportunities. Please stop by the registry table today to talk with Dr. Olmos about the benefits of participating in the MDFR.



We also invite you to stay connected beyond today and take time to review our events calendar and resources on our newly designed website! This July, we'll celebrate Myotonic Dystrophy In Motion Month—a time dedicated to movement, wellness, and community engagement, with activities for everyone: [www.myotonic.org/in-motion](http://www.myotonic.org/in-motion). We hope you will join in!

Thank you for being here, for supporting one another, and for being part of the progress ahead. If there's anything we can do to enhance your experience today, please don't hesitate to reach out.

Enjoy the conference—we're glad you're here.



*Tanya Stevenson*

Tanya Stevenson, EdD, MPH  
Chief Executive Officer

# Agenda for Saturday, May 2<sup>nd</sup>

May 2 <sup>nd</sup>	Ballroom (Room 401)	Room 409	Room 410
8:30 - 10:00 AM	Check In Opens		
9:00 - 10:00 AM	Breakfast		
10:00 - 10:45 AM	Welcome & Introduction		
10:45 - 11:00 AM	Break		
11:00 - 11:45 AM	Clinical Trials & Emerging Treatments		
11:45 - 12:00 PM	Break		
12:00 - 12:45 PM	DM1: What You Need to Know	DM2: What You Need to Know	Myotonic Dystrophy in Childhood
12:45 - 1:45 PM	Lunch		
1:45 - 2:45 PM	Industry Updates		
2:45 - 3:00 PM	Movement Moment		
3:00 - 3:15 PM	Break		
3:00 - 3:45 PM	How Myotonic Dystrophy Affects the Heart	Navigating Genetic Testing for Myotonic Dystrophy	Living with DM: Resources for Work, Disability, and Support
3:45 - 4:00 PM	Break		
4:00 - 4:45 PM	Wake Forest DM Research Showcase	Life Hacks Community Panel	
4:45 - 5:00 PM	Break		
5:15 - 6:00 PM	Stump the Doctor: DM1	Stump the Doctor: DM2	
6:00 - 7:00 PM	Reception & Networking		

# General Sessions

General sessions are for everyone! All general sessions are located in Room 401, except Stump the Doctor: DM2 which is in Room 409.

**10:00 - 10:45 AM**

## Welcome and Introduction to DM Resources

The Myotonic Dystrophy Foundation & Wake Forest University School of Medicine

MDF works to enhance the quality of life of people living with DM and to drive research focused on treatments and a cure. This session will provide an overview of the day, a summary of the work of MDF, as well as the readily available tools and resources for the community, and a feature on Wake Forest University and their work in the DM space.

**11:00 - 11:45 AM**

## Clinical Trials and Emerging Treatments

Araya Puwanant, MD, MS, Wake Forest University School of Medicine

As academic and industry partners work to develop treatments and a cure for myotonic dystrophy (DM), it is more important now than ever that the DM community is ready to participate in trials. This talk will provide an overview of clinical trials and help attendees think about how to prepare for upcoming trials and studies.



**1:45 - 2:45 PM**

## Industry Updates

Representatives from biotechnology and pharmaceutical companies will provide updates on their drug development efforts in the DM field.

**2:45 - 3:00 PM**

## Movement Moment

Christina Soriano, Reynolds Professor of Dance and Co-Director of the Wake the Arts Center and the WFU Neuroarts Lab

Join for a short, interactive movement demonstration for all conference attendees to gently get moving, stretch, and break up a full day of sessions.



**5:15 - 6:00 PM**

## Stump the Doctor

Stump the Doctor is an opportunity for community members to meet a leading expert in myotonic dystrophy and ask their most persistent challenging questions. Can you stump the doctor?

*Note, these sessions will not be recorded.*



## DM1 (Room 401)

Dr. M. Barclay McGhee, M.D. Neuromuscular Neurologist at Atrium Wake Forest Baptist Health

## DM2 (Room 409)

Araya Puwanant, MD, MS Wake Forest University School of Medicine

# Breakout Sessions

Breakout Sessions at these Regional Conferences serve a variety of community interests and needs. They have been designed with community input and have a universal focus for all people affected by DM1 or DM2 and their families.

## 12:00 - 12:45 PM (Room 401)

### DM1: What You Need to Know

Michael S. Cartwright, MD, MS, Professor of Neurology  
Wake Forest School of Medicine

This session is for those new to the DM1 community and those seeking a refresher. Join for an overview of DM1 including genetics, symptoms, self-management, and working with your clinical care team to ensure the best quality of life.



## 12:00 - 12:45 PM (Room 409)

### DM2: What You Need to Know

Araya Puwanant, MD, MS Wake Forest University School of Medicine

This session is for those new to the DM2 community and those seeking a refresher. Join for an overview of DM2 including genetics, symptoms, self-management, and working with your clinical care team to ensure the best quality of life.



## 12:00 - 12:45 PM (Room 410)

### Myotonic Dystrophy in Childhood

Jenny Harmon, MD, PhD, Assistant Professor  
Wake Forest University School of Medicine

This session is for those new to the congenital DM (CDM) community and those seeking a refresher. Join for a comprehensive overview of CDM including symptoms, management, and working with your clinical care team to ensure the best quality of life.



## 3:00 - 3:45 PM (Room 401)

### How Myotonic Dystrophy Affects the Heart

Anvi Raina, M.D., Cardiac Electrophysiology, Dept. of Cardiovascular  
Medicine, Asst Professor of Medicine, Wake Forest University Medical Center

This session covers cardiac considerations in myotonic dystrophy including how DM can affect the heart, common issues, the latest research, and best practices for care.



# Breakout Sessions

Breakout Sessions at these Regional Conferences serve a variety of community interests and needs. They have been designed with community input and have a universal focus for all people affected by DM1 or DM2 and their families.

## 3:00 - 3:45 PM (Room 409)

### Navigating Genetic Testing for Myotonic Dystrophy

Elaine Conrad, MS, CGC, MSCRM, Certified Genetic Counselor  
Department of Pediatrics, Section on Medical Genetics

Join this session to learn about genetic counseling and family planning and myotonic dystrophy. You'll get more information on what a genetic counselor is, how to get tested, and planning for the future.



## 3:00 - 3:45 PM (Room 410)

### Living with DM: Resources for Work, Disability, and Support

Emily Owen, MSW LCSW-A, Social Worker, Neurology Outpatient Clinics

This session provides practical guidance on navigating work, disability benefits, and support services while living with DM. Attendees will learn about available resources, advocacy strategies, and supports for both individuals with DM and their caregivers.



## 4:00 - 4:45 PM (Room 401)

### Wake Forest DM Research Showcase

Araya Puwanant, MD, MS Wake Forest University School of Medicine  
Diana Madrid, MS, Wake Forest University School of Medicine

This session highlights ongoing myotonic dystrophy research at Wake Forest University, showcasing current studies, key findings, and how this work advances understanding and treatment of DM. Attendees will gain insight into the research process and emerging opportunities that may shape future care and therapies.



## 4:00 - 4:45 PM (Room 409)

### Community Panel: Life Hacks

Haley Martinelli, Esq., Joanna Sacco,  
Jonna Bernstein, MD, Shaun Moore

Join MDF volunteer community leaders and community members in a discussion on everyday victories through useful tips, tricks, and adaptive devices. *Please note, this session will not be recorded.*



# Myotonic Dystrophy at a Glance

Myotonic dystrophy is the most common form of adult muscular dystrophy and considered the most variable of all known conditions. Do your part to help start conversations and educate your family, friends, and care providers about the basics of myotonic dystrophy (DM).

Myotonic dystrophy is a rare, multi-systemic, inherited disease that may affect as many as 1 in 2,100 people, or over 3 million individuals across the world.

Millions of people are living with DM globally, yet millions of people do not know they have the disease and are in need of care.

Myotonic dystrophy is the most common form of adult muscular dystrophy and considered the most variable of all known conditions.

Myotonic dystrophy is commonly referred to as DM, an abbreviation of the Latin name used by doctors and researchers worldwide: dystrophia myotonica. Other names for DM include myotonic muscular dystrophy (MMD), Steinert's Disease for DM1, and proximal myotonic myopathy (PROMM) for DM2.

Myotonic dystrophy symptoms usually become more severe with each generation, yet there is currently no cure and there are no approved treatments.

Mutations prevent genes from carrying out their functions properly, which can impact multiple body systems. Myotonic dystrophy type 1 is caused by a mutation in the DMPK gene, while myotonic dystrophy type 2 is caused by a mutation in the CNBP gene.



Myotonic dystrophy is inherited - people living with myotonic dystrophy have a 50% chance of passing on the mutated gene to their children.



People living with myotonic dystrophy experience varied and complex symptoms, from skeletal muscle problems, to heart, breathing, digestive, hormonal, speech and swallowing, diabetic, immune, excessive daytime sleepiness, early cataracts and vision challenges, and cognitive difficulties.



Myotonic dystrophy doesn't always look the same. The different body systems affected, the severity of symptoms, and the age of onset of those symptoms vary greatly between individuals, even in the same family.



Delays in diagnosing myotonic dystrophy are common. Despite the availability of simple genetic tests, a lack of familiarity with the disease on the part of healthcare providers can allow misdiagnoses to persist for decades.



Over 30 biopharmaceutical companies are leading promising research which may result in new treatments for myotonic dystrophy, and, one day, a cure.



Learn more at [www.myotonic.org/at-a-glance](http://www.myotonic.org/at-a-glance)

# MDF Resources for Individuals Affected by DM

These publications are for a general audience to help understand the condition and various aspects of life with DM. You can access them all for free on the MDF website or email us at [info@myotonic.org](mailto:info@myotonic.org) to get a hard copy mailed to you.

An \* indicates this resource is available in more than one language.



## **Practical Advice for Anesthesia for Individuals with DM & their Families\***

People living with DM may have severe and life-threatening reactions to anesthesia. This resource equips individuals living with DM and their families with crucial information to help navigate the anesthesia process.

## **Myotonic Dystrophy & the Heart: A Community Guide\***

For individuals living with myotonic dystrophy, heart or “cardiac” issues can pose a serious threat to their health. This resource aims to help people living with DM understand heart health risks and how they are managed.

## **My Clinic Visit Planner\***

This planner enables families to discuss upcoming clinic visits and jot down important questions and information to help ensure it is covered at the appointment.

## **Exercise Guide & Exercise Infographic for Individuals with Myotonic Dystrophy\***

This guide includes information on the benefits of exercise for DM, recommendations on aerobic activity, types of exercise, monitoring exercise, exercise strategies & finding motivation.

## **Nutrition Guide for Individuals with Myotonic Dystrophy\***

Developed by nutritionists experienced with DM, this guide covers information on diet and DM, managing constipation, being overweight/underweight with DM, managing swallowing problems, feeding tubes, supplements, and sample meals.

## **Applying for Social Security Disability Benefits Toolkit**

The toolkit is designed to assist those affected by DM in navigating the application process for Social Security Disability Insurance (SSDI) benefits and Supplemental Security Income (SSI) benefits. (US Health System only)

## **Mental Health Handbook\***

This resource highlights the social and emotional impact of DM, offering an overview of potential mental health challenges and available supports.

## **Medical Alert Card\***

Patients with myotonic dystrophy often exhibit adverse reactions to sedatives, anesthetics, and neuromuscular blocking agents. Ensure your emergency responders follow these critical guidelines.

## **Going to School with DM: A Guide to Understanding Special Education & IDEA**

This comprehensive resource helps parents and family members take advantage of the Individuals with Disabilities Act (IDEA). The Guide covers services and mandates for ages newborn through 21.

## **Health Insurance Considerations for People Living with DM in the US**

MDF created this resource to help you navigate the process of making sure your medical treatments and medications are covered, and how to appeal your claim if it is denied.

## **Guide for Adults Affected by Juvenile-onset (JOA) DM & their Caregivers**

This Guide is specifically designed to help families affected by juvenile-onset DM understand how to manage their lives, especially at transition points in development and education.

## **Employment Access Toolkit\***

This Toolkit helps individuals navigate employment, covering how DM may affect work, job readiness, applications, resumes, interviews, and more (U.S. job system only).

## **Planning for Adulthood: A Guide for Families & Caregivers of Children with CDM**

This guide covers key steps in preparing for the transition to adulthood for children living with CDM, including legal, educational, healthcare, and financial planning.

Learn more at [www.myotonic.org/resources](http://www.myotonic.org/resources)

# MDF Resources for Healthcare Professionals

These publications are for professional audiences – especially doctors and nurses – who treat and care for individuals living with DM. You can access them all for free on the MDF website or email us at [info@myotonic.org](mailto:info@myotonic.org) to get a hard copy mailed to you.

An \* indicates this resource is available in more than one language.



## Care Guidelines for Speech and Language Pathologists Treating Adults and Children with DM

This guide is written and reviewed by an international group of speech and language pathologists who are specialized in working with adults and children with DM.

## Clinical Care Recommendations for Cardiologists & Pulmonologists Treating Adults with DM Type 1\*

Two separate resources for cardiologists and pulmonologists that provide care recommendations for treating adults with DM1.

## Occupational Therapy Suggestions for the Management of a Myotonic Dystrophy Patient

A quick reference excerpt for clinicians from the full MDF Toolkit.

## Respiratory Care Recommendations for Myotonic Dystrophy Patients During the COVID-19 Pandemic\*

This guide includes tips for patients, caregivers, and medical providers on the use of noninvasive positive pressure ventilation (NIPPV) if you have been exposed to or have symptoms of COVID-19.

## Clinical Care Recommendations\*

Resources to improve and standardize care developed by more than 65 leading DM clinicians in Western Europe, the UK, Canada, and the US. Resources include recommendations for DM1 in adults and children, and adults with DM2.

## Clinical Recommendations for People of Pregnancy Potential with Myotonic Dystrophy\*

This resource is designed to provide clinicians with an overview of risks and care recommendations for individuals living with DM who are pregnant or considering pregnancy.

## Practical Suggestions for the Anesthetic Management of a Myotonic Dystrophy Patient\*

Regardless of the form of DM or the severity of DM symptoms experienced, severe and life-threatening reactions to anesthesia are possible and should be monitored whenever anesthesia is administered.

## The Role of Physical Therapy in the Assessment and Management of Individuals with DM












These Physical Therapy Guidelines for myotonic dystrophy address the role that the physical therapist plays in DM care.

Learn more at [www.myotonic.org/resources](http://www.myotonic.org/resources)

# Myotonic Dystrophy Drug Development Pipeline

Below is a partial snapshot of drugs for myotonic dystrophy that are currently in clinical trials. The DM Drug Development Pipeline was developed by MDF and continues to evolve based on publicly available information. Academic institutions are not included. To view the full pipeline, scan the code to the right or visit [www.myotonic.org/pipeline](http://www.myotonic.org/pipeline).



Company	Program	DM Subtype	Clinical Phase		
			1	2	3
 AMO PHARMA	Tideglusib	CDM / DM1	▶		
 AVIDITY BIOSCIENCES A Novartis Company	AOC 1001 del-desiran	DM1	▶		
 LUPIN NEUROSCIENCES	Mexiletine	DM1 / DM2	▶		
 Dyne THERAPEUTICS	Dyne 101 z-basivarsen	DM1	▶		
 ARTHEX biotech	ATX-01	DM1	▶		
 H3 HARMONY BIOSCIENCES	Pitolisant	DM1	▶		
 PepGen	PGN-EDODM1	DM1	▶		
 Juvena THERAPEUTICS	JUV-161	DM1	▶		
 VERTEX	VX-670	DM1	▶		
 sanofi	--	--	▶		
 SAREPTA THERAPEUTICS	SRP-1003	DM1	▶		

# International Myotonic Dystrophy Awareness Day

MDF is proud to be a founding member of the Global Alliance for Myotonic Dystrophy Awareness, a group of organizations and institutions from around the world working together to raise awareness of myotonic dystrophy. Learn more at: [www.myotonic.org/international-dm-day](http://www.myotonic.org/international-dm-day)



# Make the Most Out of Your Conference Experience



## First Time at an MDF Event?

MDF staff members will be wearing white lanyards and will be happy to answer any questions you may have about the conference. Look for the MDF Support Group Facilitator exhibitor table as well to learn more about supports and resources and meet community member attendees committed to helping ensure your first MDF Conference experience is a complete success!




## Make the Most of Breaks

There are many breaks built into the conference agenda so you can take care of personal needs. Use this time to snap a photo, connect with others, or visit exhibitor booths.




## Take A Photo!

Don't let your conference memories fade away: share your experience. Post on social media, tag Myotonic Dystrophy Foundation (MDF) or @MyotonicStrong, and use #MyotonicDystrophy to help raise awareness and stay connected with the community.




Don't forget to stop by the MDF step-and-repeat backdrop near registration for a fun photo background.



## Keep in Touch!

Stay connected after the conference with MDF's monthly e-newsletter, the MDF Dispatch. It shares updates on research, daily living strategies, upcoming events, and community stories to help you stay informed. Sign up at [www.myotonic.org/sign-up](http://www.myotonic.org/sign-up)



## Continue Learning with MDF



### MDF Digital Academy

Watch hours of educational and inspiring videos from DM experts whenever you like. Browse by category and interest at: [www.myotonic.org/digital-academy](http://www.myotonic.org/digital-academy).



### Meet the DM Drug Developers Webinar Series

Since 2021, MDF has hosted biotechnology and pharmaceutical partners working on treatments and cures for myotonic dystrophy in special presentations for the community. In these sessions, they share progress and answer questions. View the complete series at: [www.myotonic.org/meet-dm-drug-developers](http://www.myotonic.org/meet-dm-drug-developers)



### Explore the Updated Find a Doctor Map

Finding medical professionals who understand myotonic dystrophy is one of the most important ways to help manage its symptoms. With input from the community, MDF has compiled a database of healthcare providers with experience caring for people living with DM. Find a medical professional in your area at: [www.myotonic.org/find-a-doctor-map](http://www.myotonic.org/find-a-doctor-map)



### Ask the Expert Series

MDF's virtual Ask the Expert series is available online, featuring DM experts across many body systems. Experts in digestion, brain, heart, speech and swallowing, mental health, lungs, and more share information and answer questions. View the complete archives at: [www.myotonic.org/ask-expert-series](http://www.myotonic.org/ask-expert-series)

***Need additional support? Get One-on-One Support at 415.800.7777***

## July is DM In Motion Awareness Month!



Movement makes connections, and we're excited to bring the DM community together through weekly Movement Monday programming, Movement and Meeting Happy Hours, and more! Special thanks to our Movement Committee for their continued support and development of this initiative!



***Now through the end of July - order your limited-edition DM In Motion Awareness Month gear at [www.myotonic.org/in-motion](http://www.myotonic.org/in-motion)***

# Thank You to Our Amazing Volunteer Leaders!

## 2026 MDF Board of Directors

Thank you to our 2026 Board of Directors which is comprised of volunteer leaders from the public and private sectors, most of whom are either living with myotonic dystrophy or have loved ones living with the disease. The Board works closely with the MDF Staff and Scientific Advisory Committee. To learn more about MDF Board of Directors, visit: [www.myotonic.org/board-directors](http://www.myotonic.org/board-directors)

Jeremy Kelly • Martha Montag Brown • Elizabeth Florence, Esq • David Herbert • Andy Berglund, PhD  
Rob Campagna, MD • Belen Esparis, MD • Charles Thornton, MD • David Berman, MBA • John Cooley  
Peter DesForges • Haley Martinelli, Esq • John W. Day, MD, PhD • Thomas (Tom) McPeek

## 2026 MDF Support Group Facilitators

MDF support programs, led by trained community volunteers, create safe spaces to network, learn, and share. We would like to specially thank our Support Group Facilitators for donating their time and energy to create these unique opportunities. Learn more about our SGFs at: [www.myotonic.org/sgfs](http://www.myotonic.org/sgfs)

Alexandra LeBoeuf • Anke Klein • Ann Woodbury • Annette Rnjak • Araceli Mera • Bernhard Rogg  
Beth Feigenblatt • Bill Nuttall • Caroline Easterling • Carolyn Valek • Chuck Hunt • Cindy Hubert  
David Kugler • Emily Jones • Erin Beucler • Guillermo Zubillaga • Haley Martinelli • Jeannine DeSoi  
Jim Dolan • Jodie Howel • John Cooley • Julian Easterling • Julie LeBoeuf • Kathie Thorsland • Kathy Coletta  
Kelsey Freedman • Kim McPeek • Kim Reynolds • Kristen McClintock • Kyle Dunson • Lois Schenk  
Luke Desforges • Lynn Schneider • Marie-Claude Sauv e • Mark Coplin • Mark Planco • Mindy Kim  
Nathan Beucler • Patricia Gibson • Peggy Melton • Rob Besecker • Rose Albanese • Ryan Vogels  
Samantha Welsh • Sarah Berman • Shaun Moore • Suzanne Perkins • Ted Salwin • Tom McPeek

## Advocate for the DM Community: Your Voice Matters!



By raising awareness, we help influence research funding, therapy development, clinical trials, and care for people living with myotonic dystrophy.

*Help change the future of DM today:*

- [Educate Policymakers](#) – Learn how to engage officials to protect and expand research funding.
- [Advocate with Confidence](#) – Get tools to speak with representatives about DM research and care.
- [Share your Story](#) – Your experience can drive change.
- [Strengthen DM Support](#) – Celebrate advocacy wins and build relationships with key decision-makers.

[www.myotonic.org/Advocate](http://www.myotonic.org/Advocate)

# DM INSIGHT Survey Results




In 2025, the Myotonic Dystrophy Foundation completed DM INSIGHT, a community-informed study to better understand the real-life experiences of people affected by myotonic dystrophy. This work was made possible by members of the DM community who shared their perspectives.

This infographic highlights key findings related to daily life with DM, access to care, and support for caregivers. As new treatments move closer to reality, these insights can help guide healthcare providers, researchers, advocates, policymakers, and payors to support meaningful improvements in everyday life.

## Who Participated?

**447**  
People Living  
with DM

**238**  
Caregivers



## Access to and Satisfaction of Healthcare

People with DM & their caregivers felt their medical care was average, with differences between DM1 & DM2.

**DM1: Slightly more satisfied**

**DM2: Slightly less satisfied**

## Most Helpful Healthcare Professionals

**45%**  
Neurologists

**38%**  
General Medicine

## What Drives DM Healthcare Satisfaction?

Your confidence in knowledge of anesthesia & cardiac risk.


Confidence in your doctor's expertise in DM.

Seeing your doctor more frequently.

Shorter wait times to see your doctor.

## Aspects of the Caregiver Experience

How Caregivers Rated Their Challenges: 1 = Low, 5 = High



All seven aspects of caregiver burden are strongly connected. Struggles in one area often spill over to others.

## What are Predictors of Caregiver Burnout?

- Higher care needs means higher burden
- Fewer breaks mean higher burden

## The Biggest Challenges for Caregivers

**49%**  
Addressing emotional or behavioral changes

**45%**  
Supporting daily activities or mobility



## Living with Myotonic Dystrophy?

*We need to hear from you!*

**Join the Myotonic Dystrophy Family Registry (MDFR) today and help support DM research.**

By Joining the Registry, You Will:

- Provide critically needed information to researchers pursuing treatments & a cure for myotonic dystrophy
- Make it easier for MDF to connect you with researchers recruiting trial & study participants
- Be informed about the latest news on DM research
- Gain access to anonymous data on symptoms, demographics, & other summary information

**IT'S EASY • IT'S CONFIDENTIAL • THERE IS NO COST TO JOIN**

**Your voice counts and we need to hear from you!**

**Questions?**

Contact the MDFR coordinator:

**Sofia Olmos, PhD**

415-800-7777

[coordinator@myotonicregistry.org](mailto:coordinator@myotonicregistry.org)

[www.myotonicregistry.org](http://www.myotonicregistry.org)



**Log in now!**

[www.myotonicregistry.org](http://www.myotonicregistry.org)



# Movement Matters

Join MDF's third annual Myotonic Dystrophy In Motion Awareness Month this July and stay active and connected with the DM community.

- Movement classes each Monday in July.
- Learn safe, practical movement from DM experts.
- Community happy hours to connect with others.

*The first 100 community members who register by June 1 will receive an In Motion water bottle (U.S. only).*

[www.myotonic.org/In-Motion](http://www.myotonic.org/In-Motion)



# Raise DM Awareness on September 15th!

Join a global movement to drive research, improve care, and accelerate treatments for DM.

**Will you celebrate International DM Awareness Day?**

- Wear green and share your support on social media.
- Share the DM-At-A-Glance poster at school or work.
- Display an awareness sign in your community.
- Educate healthcare providers with MDF resources.

*Together, we can make myotonic dystrophy more visible and build a future with better care and treatments.*

[www.myotonic.org/International-DM-Day](http://www.myotonic.org/International-DM-Day)





## Community Connections

*Send a Letter, Share a Smile!*

The DM community can use your support. Many people living with myotonic dystrophy experience social isolation and may find it hard to connect. Send a heartfelt letter, drawing, or story to brighten someone's day.



Nominate a community member to receive letters.



Write a letter, share a joke, or draw a picture.



Mail or email your message, and MDF will forward it in a special care package!

*Your words can make a difference—reach out today!*

[www.myotonic.org/community-connections](http://www.myotonic.org/community-connections)

MYOTONIC DYSTROPHY FOUNDATION

# 2026 Gala

UNITING FOR A CURE

October 10, 2026

Mark Hopkins Hotel  
San Francisco, CA

[www.myotonic.org/Gala](http://www.myotonic.org/Gala)


# Fundraise Your Way!

Are you celebrating a special occasion, participating in a fitness challenge, or hosting a community event?

*You can make a difference with a fundraiser for MDF!*

Your DIY (Do It Yourself!) Fundraiser empowers our work to support the DM community, provide essential resources, and accelerate research toward treatments and a cure.

[www.myotonic.org/DIY](http://www.myotonic.org/DIY)



## Apply for MDF Research Grants!

MDF is funding innovative research to drive progress in understanding, care, and treatments for myotonic dystrophy.

### Research Fellowship - \$55k | \$105k

- Doctoral
- Postdoctoral

### Early Career Grant - \$190k

- Basic / Translational Science
- Clinical Research



### Small Grants - \$2.5k | \$5k

- Conference travel
- Open-access fees

### Pilot Grants - \$50k

[www.myotonic.org/Grants](http://www.myotonic.org/Grants)

APPLY NOW!



# Together With



**Loraine**

DMI Advocate and her family

**It is humbling and inspiring to be part of this important gathering,** and to witness the tireless work and thoughtful leadership of the Myotonic Dystrophy Foundation throughout the year. **We want to recognize and thank anyone who has participated in or inquired about our studies.** You have helped propel pioneering research forward for those living with myotonic dystrophy.

Together with you, we are advancing the understanding of this rare disease with the goal of bringing critically needed therapies to those who are waiting.

# ...Our Work Continues

**Avidity is now part of Novartis**, and we are excited to bring our global resources, passion for novel science, and relentless commitment to serving patient communities to you. **Thank you for inspiring us with your stories, educating us by sharing experiences**, and working with us to move our research program for myotonic dystrophy forward.

**With gratitude,**



**AVIDITY**<sup>®</sup>  
BIOSCIENCES

**A Novartis Company**

Dyne is on a mission to deliver

# FUNCTIONAL IMPROVEMENT

for individuals, families  
and communities

Functional improvement means small things like zipping a jacket, climbing up stairs or completing a morning routine.

We're proud to support the MDF 2026 Regional Conferences as we work toward our mission to deliver functional improvement.



To learn more visit us at our table or email [patientadvocacy@dyne-tx.com](mailto:patientadvocacy@dyne-tx.com)



©2026 Dyne Therapeutics, Inc. All rights reserved.



## ATX-01: A New Approach to DM1


The next generation of RNA medicine - delivered.



### Dual Mechanism – Brain-active – Functional Outcomes.

ATX-01 is a first-in-class oligonucleotide with a differentiated dual mechanism of action and proprietary delivery system designed to:

- ✓ Re-establish MBNL protein expression
- ✓ Correct splicing of various proteins including MBNL protein itself
- ✓ Decrease DMPK mRNA foci formation leading to reduction of DMPK mRNA
- ✓ Cross the blood-brain barrier — addressing both systemic and brain disease of DM1



### the Arthemir™ trial

A Phase 1/2a Double-Blind, Placebo-controlled, Single- and Multiple Ascending Dose Study in Classic Myotonic Dystrophy Type 1 (DM1)

www.arthemir.com  
info@arthexbiotech.com

Scan QR code for trial details

Brain-active in animal

IV dose

Mechanistically targeted

Ask about our results in adult onset and congenital DM1 mouse models



Better Technology. Better Delivery.

## Committed to transforming the lives of people living with myotonic dystrophy type 1 (DM1).

PepGen’s investigational therapy for DM1, PGN-EDODM1, is designed to act on DM1 symptoms by binding to the repeat sequence that results from the mutation that causes DM1.

PGN-EDODM1 is now being studied in clinical trials.

## Come visit our booth!



Leslie, Living with DM1

### Want to learn more?

Contact us:

Jane Larkindale, D. Phil, VP Clinical Science

Sophia Roe, Patient Advocacy Associate

Email: [Community@pepgen.com](mailto:Community@pepgen.com)

Scan the QR code to learn about our science, clinical trials, and work with the DM1 community:



© 2026 PepGen Inc. All rights reserved.



**Vertex invests in scientific innovation to create transformative medicines for people with serious diseases.**

We work with leading researchers, doctors, public health experts and other collaborators who share our vision for transforming the lives of people with serious diseases, their families and society.

Vertex is a proud supporter of the 2026 Myotonic Dystrophy Foundation Regional Conferences.

[www.vrtx.com](http://www.vrtx.com)

Vertex and the Vertex triangle logo are registered trademarks of Vertex Pharmaceuticals Incorporated.  
© 2026 Vertex Pharmaceuticals Incorporated



# **3X Genetics**

## **Targeted Genetic Testing (TGT)**

**Accelerating the diagnosis and understanding of Myotonic Dystrophy**

**FREE** Long-Repeat Testing for all DM1 Patients  
Screening Tests for DM1 & DM2

**Contact: [TGT@3xgenetics.com](mailto:TGT@3xgenetics.com)**



This image depicts a family living with myotonic dystrophy type 1 (DM1)

## Patients are at the heart of everything we do at Astellas

Our Patient Centricity vision is to enable a future for Astellas where all healthcare innovation is driven by the needs of patients and caregivers. At Astellas we develop medicines by connecting patient and caregiver experiences at every stage of our medicines' development – from early research through to delivery and beyond.

Patients are the reason why Astellas exists, and they are the driving force at the center of everything we do.

**PATIENTS ARE WHY™**



Find out more at:

[astellas.com/en/about/patient-centricity](https://astellas.com/en/about/patient-centricity) [in](#) [f](#) [X](#) [@AstellasUS](#)



## The BrAAVe Study is a gene therapy clinical research study for persons living with myotonic dystrophy type 1 (DM1).

The purpose of this research study is to evaluate the safety and efficacy of the gene therapy investigational study drug in persons living with DM1. Our hope is to see if the investigational gene therapy can safely help them and improve their quality of life.

### You may qualify for this study if you:

- Are 18 to 50 years of age.
- Have been diagnosed with non-congenital DM1, presenting with signs of myotonia and muscle weakness.

If you are interested in learning more about the research study, talk to your doctor or visit our website.

### Interested in learning more?



Intended for U.S. Audiences Only. ©2025 Sanofi US Services, Inc. All Rights Reserved. Sanofi - BrAAVe Study - Recruitment Flyer - 14-Mar-2025 - English (Principal) - V1.1 [BrAAVe-RF-EnP]




## Juvena's mission is to reJjuvenate lives with Medicine for Movement



## Pioneering therapeutics for myopathies and metabolic diseases

There are no currently approved muscle regeneration therapies for myotonic dystrophy, despite a significant unmet need. We combined our diverse library of stem-cell secreted proteins with our proprietary AI-enabled JuvNET platform to discover and translate our pipeline of biologic candidates.

### The Juvena Solution



## Restoring muscular and metabolic function through innovative biologics

Myopathies and metabolic diseases can result from a breakdown within the complex intercellular protein signaling pathways in the body. Until now, the available tools for mapping this biology limited the development of regenerative therapies and a significant unmet need exists. Juvena targets the dysregulation of proteins by engineering novel biologics to restore tissue homeostasis.

